"Since that time, it has been learned that UPI-928 is an unusual agent with many mechanisms of action, including direct cytotoxic actions, immunologic mechanisms and genomic effects. Immunologically, UPI-928 has been found to activate immune responses in a manner that can cure tumors in allogeneic transplant models. Further, it binds to DNA at a site that displaces telomerase binding proteins, which enables tumor cells to regain their mortality, become senescent and die of old age," Update Pharma notes on its website.
Update Pharma has filed new intellectual property on this compound, and plans to accelerate the development process by way of existing regulatory mechanisms, based on the current and historical data.
REON's pipeline, at present, contains three main product candidates: oxaliplatin, paclitaxel and ROI-1301. Oxaliplatin RTU, a nucleoside analogue, is a small-molecule, injectable chemotherapy agent for adjuvant treatment of colon cancer and advanced colorectal cancer. Paclitaxel RTU, an anti-mitotic, small-molecule chemotherapy agent, is indicated for standard-of-care treatment regimens for lung, breast and prostate cancers, among others. Both are ready-to-use liquid formulations, and are slated to be launched this year. ROI-1301 is a development-stage biologic product for the treatment of chemotherapy-induced neutropenia, a shortage of white blood cells, known as neutrophils, caused by chemotherapy's attack on dividing cells. Neutrophils are one of the types of white blood cells that help to fight infection, and facing a shortage of these cells, when already dealing with cancer and chemotherapy, is a serious concern for cancer patients. ROI-1301 is expected to launch in 2016.
This person does not yet have a bio.View Full Profile
